MILAN, Italy & MORRISTOWN, New Jersey & SEOUL, Republic of Korea–(BUSINESS WIRE)—- $NWRN #schizophrenia–Newron and Myung In Pharm, South Korea’s leading specialist CNS pharma company, announce license agreement for evenamide in South Korea.

BOSTON–(BUSINESS WIRE)–PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

SAN MATEO, Calif.–(BUSINESS WIRE)–Mendaera Inc., a healthcare technology company creating a first-of-its-kind handheld robotic platform to revolutionize the delivery of prevalent interventional procedures, today announced the appointment of Eric Davidson as its first Chief Commercial Officer (CCO). Davidson will lead commercialization efforts as the company prepares for market entry with its novel robotic technologies. Davidson joins Mendaera with more than two decades of leadership in medica

MELVILLE, N.Y.–(BUSINESS WIRE)–Henry Schein, Inc. (Nasdaq: HSIC) reminds its customers throughout California that the Henry Schein Customer Emergency Support Hotline is open for dental and medical professionals who may experience operational, logistical, or financial issues as a result of damage caused by the ongoing fires. The toll-free number for all Henry Schein customers is 800-999-9729. The hotline is open 24/7, with real-time assistance available from Team Schein Members from 8 a.m. to

SEATTLE–(BUSINESS WIRE)–Cyrus Biotech today announced that its protease CYR212 has been selected as its clinical candidate for chronic IgG-driven autoimmune diseases.

LEIDEN, Netherlands–(BUSINESS WIRE)– #Adults–Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that it will present at J.P. Morgan’s 43rd Annual Healthcare Conference on Thursday, January 16, 2025. The company’s presentation will begin at 8:30 a.m. PT/11:30 am (Eastern Time). The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with n

LONDON & SAN FRANCISCO–(BUSINESS WIRE)–Verdiva Bio Limited (“Verdiva” or “the Company”) today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. The Company is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. Verdiva launches with an oversubscribed Series A financing of $411M, co-led by Forbion and General Atlantic,